|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastroenterologist perceptions of faecal microbiota transplantation显示文摘AIM: To explore gastroenterologist perceptions towards and experience with faecal microbiota transplantation(FMT).METHODS: A questionnaire survey consisting of 17 questions was created to assess gastroenterologists' attitude towards and experience with FMT. This was anonymously distributed in hard copy format amongst attendees at gastroenterology meetings in Australia between October 2013 and April 2014. Basic descriptive statistical analyses were performed.RESULTS: Fifty-two clinicians participated. Twenty one percent had previously referred patients for FMT,8% more than once. Ninety percent would refer patients with Clostridium difficile infection(CDI) for FMT if easily available,37% for ulcerative colitis,13% for Crohn's disease and 6% for irritable bowel syndrome. Six percent would not refer any indication,including recurrent CDI. Eighty-six percent would enroll patients in FMT clinical trials. Thirty-seven percent considered the optimal mode of FMT administration transcolonoscopic,17% nasoduodenal,13% enema and 8% oral capsule. The greatest concerns regarding FMT were: 42% lack of evidence,12% infection risk,10% non infectious adverse effects/lack of safety data,10% aesthetic,10% lack of efficacy,4% disease exacerbation,and 2% inappropriate use; 6% had no concerns. Seventy seven percent believed there is a lack of accessibility while 52% had an interest in learning how to provide FMT. Only 6% offered FMT at their institution.CONCLUSION: Despite general enthusiasm,most gastroenterologists have limited experience with,or access to,FMT. The greatest concerns were lack of supportive evidence and safety issues. However a significant proportion would refer indications other than CDI for FMT despite insufficient evidence. These data provide guidance on where education and training are required. | Sudarshan Paramsothy Alissa J Walsh Thomas Borody Douglas Samuel Johan van den Bogaerde Rupert WL Leong Susan Connor Watson Ng Hazel M Mitchell Nadeem O Kaakoush Michael A Kamm | 2015 | World Journal of Gastroenterology2015，21，38： | 5 |
| 2 | Treating Clostridium difficile Infection With Fecal Microbiota Transplantation显示文摘 | Johan S. Bakken Thomas Borody Lawrence J. Brandt Joel V. Brill Daniel C. Demarco Marc Alaric Franzos Colleen Kelly Alexander Khoruts Thomas Louie Lawrence P. Martinelli Thomas A. Moore George Russell Christina Surawicz | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 5 |
| 3 | Fecal Microbiota Transplantation显示文摘 | Thomas Julius Borody Jordana Campbell | 2012 | Gastroenterology Clinics of North America2012，，4： | 3 |
| 4 | Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions显示文摘 | Thomas J. Borody Sudarshan Paramsothy Gaurav Agrawal | 2013 | Current Gastroenterology Reports2013，，8： | 3 |
| 5 | Therapeutic Potential of Fecal Microbiota Transplantation显示文摘 | Loek P. Smits Kristien E.C. Bouter Willem M. de Vos Thomas J. Borody Max Nieuwdorp | 2013 | Gastroenterology2013，，5： | 2 |
| 6 | Therapeutic faecal microbiota transplantation: current status and future developments显示文摘 | Thomas J. Borody Lawrence J. Brandt Sudarshan Paramsothy | 2014 | Current Opinion in Gastroenterology2014，，1： | 1 |
| 7 | Treating Clostridium difficile Infection With Fecal Microbiota Transplantation显示文摘 | Johan S. Bakken Thomas Borody Lawrence J. Brandt Joel V. Brill Daniel C. Demarco Marc Alaric Franzos Colleen Kelly Alexander Khoruts Thomas Louie Lawrence P. Martinelli Thomas A. Moore George Russell Christina Surawicz | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 1 |
| 8 | Treatment of Ulcerative Colitis Using Fecal Bacteriotherapy显示文摘 | Thomas J. Borody Eloise F. Warren Sharyn Leis Rosa Surace Ori Ashman | 2003 | Journal of Clinical Gastroenterology2003，，1： | 1 |
| 9 | Could fecal microbiota transplantation cure all Clostridium difficile infections?显示文摘 | Borody Thomas J Peattie Debra Kapur Amit | 2014 | Future Microbiology2014，，1： | 1 |
| 10 | Fecal Microbiota Transplantation显示文摘 | Thomas Julius Borody Jordana Campbell | 2012 | Gastroenterology Clinics of North America2012，，4： | 1 |
| 11 | Durable Alteration of the Colonic Microbiota by the Administration of Donor Fecal Flora显示文摘 | Martin J. Grehan Thomas Julius Borody Sharyn M. Leis Jordana Campbell Hazel Mitchell Antony Wettstein | 2010 | Journal of Clinical Gastroenterology2010，，8： | 1 |
| 12 | Is Crohn’s Disease Ready for Fecal Microbiota Transplantation?显示文摘 | Thomas J. Borody Sarah Finlayson Sudarshan Paramsothy | 2014 | Journal of Clinical Gastroenterology2014，，7： | 1 |
| 13 | Bacteriotherapy Using Fecal Flora: Toying With Human Motions显示文摘 | Thomas J Borody Eloise F Warren Sharyn M Leis Rosa Surace Ori Ashman Steven Siarakas | 2004 | Journal of Clinical Gastroenterology2004，，6： | 1 |
| 14 | Treating Clostridium difficile Infection With Fecal Microbiota Transplantation显示文摘 | Johan S. Bakken Thomas Borody Lawrence J. Brandt Joel V. Brill Daniel C. Demarco Marc Alaric Franzos Colleen Kelly Alexander Khoruts Thomas Louie Lawrence P. Martinelli Thomas A. Moore George Russell Christina Surawicz | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 1 |
| 15 | Treatment of Ulcerative Colitis Using Fecal Bacteriotherapy显示文摘 | Thomas J. Borody Eloise F. Warren Sharyn Leis Rosa Surace Ori Ashman | 2003 | Journal of Clinical Gastroenterology2003，，1： | 1 |
| 16 | Crohn’s strictures open with anti-mycobacterial antibiotic therapy:A retrospective review显示文摘BACKGROUND Medical therapy for strictures is limited and first-line treatment consists of endoscopic balloon dilatation,strictureplasty or surgical resection.Mycobacterium tuberculosis,Helicobacter pylori and Streptococcus can all cause stenosis,for which antibiotic treatment achieves stricture resolution.Mycobacterium avium ssp.paratuberculosis is a suspected causative agent in Crohn’s disease(CD).Thus,specialized antimicrobial treatment,in particular,anti-mycobacterial antibiotic therapy(AMAT)has been proposed as a potential treatment option.To our knowledge,the opening of CD strictures has not been recorded using any form of antibiotic therapy.We hypothesized that AMAT would resolve strictures in patients with CD.AIM To investigate the effect and outcomes of AMAT in a cohort of CD patients with an ileal stricture.METHODS A single center,retrospective,medical record case review was conducted on an observational cohort of patients with CD who had an ileal stricture on colonoscopy and were treated with AMAT.Forty patients meeting the inclusion criteria were identified from the internal medical database.Thirty(75%)patients had follow-up colonoscopy and clinical data available.The AMAT regimen was prescribed after the initial colonoscopy for a duration of at least six months until follow-up colonoscopy with the attending gastroenterologist.Patient demographics,symptoms,colonoscopy reports,inflammatory serum markers and concurrent medications were recorded at pre-treatment and follow-up between January 1995 and June 2018.RESULTS Of the patients that returned for follow-up after>24 mo of AMAT,twenty(67%)had complete resolution(CR)of their ileal strictures,three(10%)had partial resolution and seven(23%)had no resolution.Irrespective of stricture outcome,21 patients(70%)demonstrated clinical response to AMAT and there was a statistically significant reduction in inflammatory serum markers C-reactive protein(P<0.0001)and erythrocyte sedimentation rate(P=0.04)from pretreatment to follow-up.It was observed that 11(37%)patients experienced side effects,but no serious adverse effects were attributable to AMAT.At follow-up there were 26(87%)patients on concomitant medication for CD and a statistically significant association between CR and AMAT with a concomitant immunomodulator(P=0.02).CONCLUSION This study demonstrated a high rate of stricture resolution(67%)similar to that seen in tuberculosis strictures(70%),suggesting a shared mycobacterial origin of strictures,and perhaps disease. | Rhys Collyer Annabel Clancy Gaurav Agrawal Thomas J Borody | 2020 | World Journal of Gastrointestinal Endoscopy2020，12，12： | 0 |
| 17 | Two-day enema antibiotic therapy for parasite eradication and resolution of symptoms显示文摘BACKGROUND Blastocystis hominis(B.hominis)and Dientamoeba fragilis(D.fragilis)are two protozoan parasites of human bowel that are found throughout the world.There is still debate about the pathogenicity of these protozoans,despite them being commonly associated with gastrointestinal symptoms and can cause health issue in both children and adults.These parasites are usually transmitted through faecal-oral contact particularly under poor hygiene conditions or food/water contamination.Once a person is infected,the parasites live in the large intestine and are passed in the faeces.AIM To investigate the effect of triple antibiotic therapy using enema infusion in the treatment of B.hominis and D.fragilis infections.METHODS This retrospective longitudinal study was conducted in a single medical centre,which included fifty-four patients(≥18 years)who were positive for D.fragilis,B.hominis or both between 2017 and 2018.The treatment consisted of triple antibiotics that were infused over two consecutive days through rectal enema.Faecal samples were collected from participants pre-and post-treatment and were tested for parasites using microscopy and polymerase chain reaction.Patients’symptoms were recorded prior and after the treatment as well as patient demographic data.RESULTS Patients(n=54),were either positive for B.hominis(37%),D.fragilis(35%)or both(28%).All patients completed the two-day treatment and no serious adverse effect was reported.The most common side effect experienced by the patients during the treatment was urine discolouration which was cleared by six weeks of followup.Common symptoms reported prior to treatment were diarrhoea,abdominal pain,constipation and fatigue.Other symptoms included abdominal discomfort,dizziness and blood in the stool.Eighty-nine percent of patients completed a final stool test post-treatment.At six weeks post-treatment,79%of patients cleared the parasites from their faeces.Symptoms such as abdominal discomfort,dizziness and blood in the stool decreased significantly at both seven days and six weeks post-treatment(P<0.040).The enema retention time,bowel preparation,previous antibiotic treatment or previous gastrointestinal problems had no significant effect on parasite eradication.CONCLUSION Overall,eradication of parasites and improvement of clinical outcomes were observed in treated patients,showing the efficacy of this combination to eradicate the parasites and provide positive clinical outcome. | Niloufar Roshan Annabel Clancy Anoja W Gunaratne Antoinette LeBusque Denise Pilarinos Thomas J Borody | 2020 | World Journal of Gastroenterology2020，26，26： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员